Health In Tech, Inc. (HIT)
NASDAQ: HIT · Real-Time Price · USD
1.440
+0.020 (1.41%)
At close: Apr 2, 2026, 4:00 PM EDT
1.460
+0.020 (1.39%)
After-hours: Apr 2, 2026, 4:26 PM EDT
Health In Tech Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Health In Tech stock has a target of 2.50, which predicts a 73.61% increase from the current stock price of 1.44.
Price Target: $2.50 (+73.61%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Jun 26, 2025.
Analyst Ratings
According to 1 stock analyst, the rating for Health In Tech is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 |
|---|---|---|
| Strong Buy | 1 | 1 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
| Total | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Strong Buy Initiates $2.5 | Strong Buy | Initiates | $2.5 | +73.61% | Jun 26, 2025 |
Financial Forecast
Revenue This Year
42.46M
from 33.33M
Increased by 27.39%
Revenue Next Year
80.91M
from 42.46M
Increased by 90.58%
EPS This Year
-0.01
from 0.02
EPS Next Year
0.19
from -0.01
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 |
|---|---|---|
| High | 45.3M | 84.1M |
| Avg | 42.5M | 80.9M |
| Low | 40.1M | 78.5M |
Revenue Growth
| Revenue Growth | 2026 | 2027 |
|---|---|---|
| High | 35.9% | 98.1% |
| Avg | 27.4% | 90.6% |
| Low | 20.4% | 84.9% |
EPS Forecast
| EPS | 2026 | 2027 |
|---|---|---|
| High | - | 0.20 |
| Avg | -0.01 | 0.19 |
| Low | -0.01 | 0.19 |
EPS Growth
| EPS Growth | 2026 | 2027 |
|---|---|---|
| High | - | - |
| Avg | - | - |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.